Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …

Objective To evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent
for treating coronavirus 2019 (COVID-19). Methods A retrospective cohort study was …

Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …

Abstract Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …

Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

Background Real-world clinical data to support the use of casirivimab–imdevimab for the
treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is …